Clinical Trial Update: A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating camrelizumab plus rivoceranib mesylate versus investigator's choice in advanced hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• rivoceranib mesylate (rivoceranib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Status: TERMINATED